HROW.US Harrow Health Inc

Healthcare Pharmaceuticals USA Stocks
30.12 USD
Close of Nov 15, 2026
25.76 54.85
Market cap
USD 1.13B
P/E
-
P/B
38.73x
ROE
-160.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HROW.US undervalued?

Graham number

The Graham number of Harrow Health Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Harrow Health Inc fundamental analysis

No fundamental analysis for Harrow Health Inc yet.

Harrow Health Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Harrow Health Inc

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; I…

Full company profile